Patient characteristics in
EMPOWER-Lung 11,2

Patient characteristics in EMPOWER-Lung 1 Patient characteristics in EMPOWER-Lung 1
  • In the subset of patients with known PD-L1 ≥50% (n=563), baseline patient and disease characteristics were consistent with those
    in the ITT population1,2

References: 1. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. Supplementary material available at: https://www.sciencedirect.com/science/article/abs/pii/S0140673621002282. Accessed February 13, 2021. 2. Data on file. Regeneron Pharmaceuticals, Inc.